12
Participants
Start Date
June 16, 2022
Primary Completion Date
November 10, 2022
Study Completion Date
January 19, 2023
T-Guard
T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
Ruxolitinib
Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
Mount Sinai Medical Center, New York
Wake Forest University, Winston-Salem
Duke University Medical Center, Durham
H. Lee Moffitt Cancer Center, Tampa
University of Alabama, Birmingham
Sarah Cannon Research Institute, Nashville
Ohio State University, Columbus
University of Wisconsin, Madison
Washington University St. Louis, St Louis
University of Utah, Salt Lake City
City of Hope National Medical Center, Duarte
Oregon Health & Science University, Portland
Site BE300, Brussels
Site BE301, Brussels
Site BE307, Ghent
Site BE305, Leuven
Site BE302, Liège
Site BE303, Yvoir
Site HR320, Zagreb
Site FR341, Angers
Site FR345, Créteil
Site FR346, La Tronche
Site FR355, Lille
SiteFR354, Nantes
SiteFR342, Paris
SiteFR348, Paris
Site FR356, Pierre-Bénite
Site FR351, Saint-Priest-en-Jarez
Site FR352, Toulouse
Site DE367, Dresden
Site DE364, Essen
Site DE371, Hanover
Site DE368, Heidelberg
Site DE360, Leipzig
Site DE362, Mainz
Site DE361, Münster
Site IT384, Milan
Site NL461, Groningen
Site NL460, Maastricht
Site NL463, Nijmegen
Site ES447, Barcelona
Site ES446, Madrid
Site ES442, Salamanca
Site ES451, Santander
Site ES452, Seville
Site ES453, Valencia
Site ES454, Valencia
Site GB483, Cardiff
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Blood and Marrow Transplant Clinical Trials Network
NETWORK
National Cancer Institute (NCI)
NIH
National Marrow Donor Program
OTHER
Xenikos
INDUSTRY